T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccinationNiels J M Verstegen, Ruth R Hagen, Christine Kreher, Lisan H Kuijper, Jet van den Dijssel, Thomas Ashhurst, Laura Y L Kummer, Virginia Palomares Cabeza, Maurice Steenhuis, Mariël C Duurland, Rivka de Jongh, C Ellen van der Schoot, Veronique A L Konijn, Erik Mul, Katherine KedzierskaSee the full list of authors
28 March 2024
COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year studyFederico Montini, Agostino Nozzolillo, Nicolò Tedone, Damiano Mistri, Paola MV Rancoita, Chiara Zanetta, Alessandra Mandelli, Roberto Furlan, Lucia Moiola, Vittorio Martinelli, Maria A Rocca, Massimo Filippi,
19 October 2023
Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?Lina Jeantin, Basma Abdi, Cathia Soulié, Delphine Sterlin, Elisabeth Maillart, Ysoline Beigneux, Amandine Hippolyte, Lisa Belin, Anne-Geneviève Marcelin, Valérie Pourcher, Céline Louapre
21 July 2023
Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levelsJulie A Campbell, Ingrid van der Mei, Bruce V Taylor, Andrew J Palmer, Glen J Henson, Laura Louise Laslett, Steve Simpson-Yap, Suzi B Claflin
26 October 2023
Advances in diagnosis and management of distal sensory polyneuropathiesMatthew Silsby, Eva L Feldman, Richard D Dortch, Alison Roth, Simon Haroutounian, Yusuf A Rajabally, Steve Vucic, Michael E Shy, Anne Louise Oaklander, Neil G Simon
30 March 2023
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine dosesFrederik Novak, Hamza Mahmood Bajwa, John Eugenio Coia, Anna Christine Nilsson, Christian Nielsen, Dorte K Holm, Kamilla Østergaard, Mathilde Vilhelmine Miller Hvidt, Keld-Erik Byg, Isik S Johansen, Kristen Mittl, William Rowles, Scott S Zamvil, Riley Bove, Joseph J SabatinoSee the full list of authors
25 April 2023
Correspondence on functional neurological disorders after COVID-19 and SARS-CoV-2 vaccinesAmnuay Kleebayoon, Viroj Wiwanitkit
7 April 2023
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational studyAraceli Alonso-Canovas, Monica M Kurtis, Victor Gomez-Mayordomo, Daniel Macías-García, Álvaro Gutiérrez Viedma, Elisabet Mondragón Rezola, Javier Pagonabarraga, Lidia Aranzabal Orgaz, Jaime Masjuan, Juan Carlos Martinez-Castrillo, Isabel Pareés
8 March 2023
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunologyKeigo Kihara, Makoto Kinoshita, Tomoyuki Sugimoto, Shuhei Okazaki, Hisashi Murata, Shohei Beppu, Naoyuki Shiraishi, Yasuko Sugiyama, Toru Koda, Tatsusada Okuno, Hideki Mochizuki
3 January 2023
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapiesAlessandra Aiello, Andrea Coppola, Serena Ruggieri, Chiara Farroni, Anna Maria Gerarda Altera, Andrea Salmi, Valentina Vanini, Gilda Cuzzi, Linda Petrone, Silvia Meschi, Daniele Lapa, Aurora Bettini, Shalom Haggiag, Luca Prosperini, Simonetta GalganiSee the full list of authors
15 December 2022